Advocacy Update: Protect FTD Research Today!
Calling all AFTD advocates – federal funding for FTD research is at risk, and we need your advocacy to protect it. Earlier this month, the National Institutes of Health announced that it will drastically change how its grants are funded. This abrupt reduction will slow progress in research focused on FTD and other diseases, as…
Read MoreMarch 13, 2025: Northern Fort Myers, FL In-Person Meet & Greet
Join and learn from others who understand the FTD journey at this in-person AFTD Meet & Greet event, hosted by AFTD volunteer Julie Moore and starting at 10:00 a.m. on Thursday, March 13. The event will be held at Palmetto Landing Amenities Center and Clubhouse, located at 44304 Palm Frond Drive in Punta Gorda. Email…
Read MoreNorthern Fort Myers, FL In-Person Meet & Greet
Join and learn from others who understand the FTD journey at this in-person AFTD Meet & Greet event, hosted by AFTD volunteer Julie Moore. Email Julie at juliemoore2016@gmail.com to RSVP for this event. Download this flyer to learn more.
Read MoreFTD Researchers Call for Greater Focus on Diversity to Address Disparities in Care and Research
An article published in the journal Alzheimer’s & Dementia identifies gaps in current FTD research caused by disparities in access to proper dementia care and research centers, and outlines ways to address these obstacles in order to further diversity in FTD science globally. The article was a collaborative effort by FTD experts worldwide through the…
Read MoreThe Lived Experience of FTD: FTD and Intimacy
In the following article, Anne Fargusson, RN, a member of the Persons with FTD Advisory Council, writes about intimacy and FTD. Intimacy can be an uncomfortable word. Years ago, when my husband and I were in premarital counseling, the therapist referred to it as “conjugation.” At the time, I had no idea what he meant;…
Read MoreVesper Bio Clinical Trial for FTD-GRN Enters Phase Ib/IIa
Danish biotechnology company Vesper Bio announced in January that its clinical trial for a potentially disease-modifying drug for FTD-GRN is proceeding to phase Ib/IIa. In FTD caused by an inherited GRN mutation, the production of the neuroprotective protein progranulin is suppressed. The protein sortilin contributes to the loss of progranulin by binding to it and…
Read More
